Gossamer Bio, Inc. (GOSS)
10.97
-0.27
(-2.40%)
USD |
NASDAQ |
Nov 13, 16:00
10.92
-0.05
(-0.46%)
After-Hours: 19:59
Gossamer Bio Total Liabilities (Quarterly) : 187.13M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 187.13M |
| June 30, 2026 | 170.90M |
| March 31, 2026 | 290.38M |
| December 31, 2025 | 295.01M |
| September 30, 2025 | 291.15M |
| June 30, 2025 | 287.03M |
| March 31, 2025 | 286.84M |
| December 31, 2024 | 285.80M |
| September 30, 2024 | 296.74M |
| June 30, 2024 | 291.92M |
| March 31, 2024 | 232.64M |
| December 31, 2023 | 249.15M |
| September 30, 2023 | 243.31M |
| June 30, 2023 | 244.55M |
| March 31, 2023 | 248.36M |
| December 31, 2022 | 260.37M |
| September 30, 2022 | 267.19M |
| June 30, 2022 | 262.30M |
| Date | Value |
|---|---|
| March 31, 2022 | 264.52M |
| December 31, 2021 | 222.19M |
| September 30, 2021 | 217.23M |
| June 30, 2021 | 211.82M |
| March 31, 2021 | 210.38M |
| December 31, 2020 | 218.75M |
| September 30, 2020 | 212.08M |
| June 30, 2020 | 204.75M |
| March 31, 2020 | 65.02M |
| December 31, 2019 | 74.12M |
| September 30, 2019 | 70.88M |
| June 30, 2019 | 65.73M |
| March 31, 2019 | 35.69M |
| December 31, 2018 | 21.12M |
| September 30, 2018 | 15.59M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 7.307M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| United Therapeutics Corp. | 758.10M |
| Arbutus Biopharma Corp. | 253.95M |
| ACADIA Pharmaceuticals, Inc. | 406.66M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Anika Therapeutics, Inc. | 52.02M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 64.34M |
| Shareholders Equity (Quarterly) | -122.80M |
| Debt to Equity Ratio | -0.3327 |
| Current Ratio | 0.6046 |
| Net Debt Paydown Yield | 44.70% |